Thermo Fisher Scientific has launched the scalable Diomni Enterprise Software for molecular diagnostics labs and test developers.

The software has been developed for streamlining routine diagnostics testing for standardisation and rapid time-to-results.

It can enhance the potential of a lab to dynamically respond to quickly changing testing environments by connecting workflow steps within a single interface.

A variety of labs can use the new software to carry out quantitative polymerase chain reaction (qPCR) diagnostic tests. It also allows developers to maximise the innovation speed for emerging testing solutions.

For improving the productivity of qPCR workflows, the software seamlessly links the individual workflow steps in one unified platform.

Furthermore, it enables labs to automate the interface with existing laboratory information systems for improved traceability.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Diomni Enterprise supports various testing workflows, including compatibility with research-use-only and in vitro tests and instruments.

Thermo Fisher Scientific qPCR instruments general manager and vice-president Fernando Beils said: “During the pandemic, we worked to quickly launch a digital solution that would allow clinical labs to continue operations, taking into account the dramatic changes in the PCR testing landscape.

“What followed was the earliest stages of the Diomni solution, delivering a digital platform that supports testing workflows with the flexibility required to accommodate rapidly evolving needs.

“We have continued to build on this platform and are excited to deliver a more robust and scalable tool for labs and assay developers across testing environments.”

In May this year, Thermo Fisher entered a partnership agreement with Pfizer to increase localised access to next-generation sequencing-based testing for cancer patients in international markets.